Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Return on Capital Employed (2016 - 2025)

IGC Pharma (IGC) has disclosed Return on Capital Employed for 15 consecutive years, with 0.29% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed rose 92.0% to 0.29% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.29%, a 92.0% increase, with the full-year FY2025 number at 0.21%, up 66.0% from a year prior.
  • Return on Capital Employed was 0.29% for Q3 2025 at IGC Pharma, down from 0.15% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.06% in Q2 2021 to a low of 1.3% in Q2 2024.
  • A 5-year average of 0.62% and a median of 0.67% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: tumbled -61bps in 2022, then surged 114bps in 2025.
  • IGC Pharma's Return on Capital Employed stood at 0.15% in 2021, then tumbled by -361bps to 0.71% in 2022, then crashed by -37bps to 0.98% in 2023, then decreased by -19bps to 1.16% in 2024, then soared by 75bps to 0.29% in 2025.
  • Per Business Quant, the three most recent readings for IGC's Return on Capital Employed are 0.29% (Q3 2025), 0.15% (Q2 2025), and 0.22% (Q1 2025).